Product How it works Pricing Blog FAQ About Contact
Crescent Biopharma

Crescent Biopharma (NASDAQ: CBIO) net income

Crescent Biopharma reported a net loss of $153.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $37.9m.

Crescent Biopharma's best year of the last 10 was fiscal 2016. It reported a loss in 10 of those 10 years.

Net income, in millions of US dollars-31.82016-33.32017-48.32018-57.92019-51.02020-63.42021-46.72022-36.92023-37.92024-153.92025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Net income by fiscal year

Fiscal yearNet incomeChangeNet marginEarnings per share
2025−$153.9m—−1,419.6%—
2024−$37.9m——−$0.59
2023−$36.9m—−368,994.2%−$0.58
2022−$46.7m—−62,251.7%−$0.89
2021−$63.4m—−5,469.0%−$1.23
2020−$51.0m—−502.1%−$1.12
2019−$57.9m——−$1.34
2018−$48.3m———
2017−$33.3m———
2016−$31.8m—−171,945.1%—

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Crescent Biopharma net income compared with its sector

By net income for its latest fiscal year, Crescent Biopharma ranks 383rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Crescent Biopharma, −1,419.6%.

RankCompanyNet incomeNet margin
381stCaribou Biosciences−$148.1m−1,327.4%
382ndUroGen Pharma−$153.5m−139.8%
383rdCrescent Biopharma−$153.9m−1,419.6%
384thMineralys Therapeutics−$154.7m—
385thSpyre Therapeutics−$155.2m—

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the net income of Crescent Biopharma

How much did Crescent Biopharma earn in fiscal 2025?
Crescent Biopharma reported a net loss of $153.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $37.9m.
Where does Crescent Biopharma rank in its sector by net income?
It ranks 383rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
Where do the figures for Crescent Biopharma come from?
From the annual report (Form 10-K) that Crescent Biopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Crescent Biopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Crescent Biopharma: the Crescent Biopharma page · annual accounts · revenue · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.